Global medical and pharmaceutical executive Carlo Montagner founded Specialised Therapeutics in Australia in 2007 following a successful international career holding senior roles at some of the world’s largest pharmaceutical companies in the United States, Europe, China, Japan and Australia.
He is a former President of Abraxis Bioscience Inc and a former Global Head of Bayer-Schering Oncology. He also served as a Global Team Leader of Sanofi-Aventis Oncology and a Hospital Business Unit Head of Aventis Australia, as well as serving as a Director of the Hospital Business Unit at Rhone-Poulenc Rorer.
Under Carlo’s leadership, Specialised Therapeutics has successfully commercialised nine speciality products spanning oncology, haematology, supportive care, emerging as the largest independent pharma company in Australia.
Carlo holds a Master of Science (Psychology) from RMIT University in Melbourne, Australia.
Specialised Therapeutics Co-Founder and Human Resources Director, Bozena Zembrzuski, is a published molecular biologist and highly experienced pharmaceutical executive. She is a former Director of CNS Business Development with global pharmaceutical giant Novartis in the United States and has also held a range of senior management roles with Novartis Australia. Bozena holds a Bachelor of Science (Hons) degree in Biological Sciences from Latrobe University in Melbourne, Australia.
Specialised Therapeutics prides itself on the calibre of its people. Our management team is comprised of leaders who have many years experience gained at some of the world’s biggest pharmaceutical companies, bringing their knowledge across medical, regulatory, marketing, sales and communications departments to our company. This expertise cements Specialised Therapeutics' standing as the largest independent pharmaceutical company in Australia.
Our team has successfully commercialised nine speciality products in less than a decade, navigating complex registration and regulatory pathways for products spanning oncology, haematology, neurosurgery, supportive care, genomic assays and ophthalmology. In addition, our specialist in-field personnel* have been consistently ranked as market leaders for their product and disease knowledge, professionalism and customer focus by independent industry sources.
* IMS Syndicated Survey of Australian Medical Oncologists – July-Oct 2011